Targeted deletion of Txndc5 in lung fibroblasts by tamoxifen injection in Col1a2-Cre/ERT2*Txndc5fl/fl mice since Day 7 after BLM instillation (the efficiency of TXNDC5/Txndc5 reduction in fibrotic mouse lungs was shown in Supplementary Fig. 12a, b), however, significantly attenuated the expansion of picrosirius red-positive areas and the increases in hydroxyproline content on Day 21 post-BLM treatment, suggesting a lessened degree of PF progression, comparing to BLM-treated control mice. The gene discussed is MAPK3; the disease is pemphigus foliaceus.